ANTIVIRAL ACTIVITY, SAFETY, AND TOLERABILITY OF MULTIPLE ASCENDING DOSES OF ELBASVIR OR GRAZOPREVIR IN PARTICIPANTS INFECTED WITH HEPATITIS C VIRUS GENOTYPE-1 OR -3 ArticleYeh W.W., Fraser I.P., Jumes P., Petry A., Lepeleire I.D., Robberechts M., Reitmann C., Huang X., Guo Z., Panebianco D., Nachbar R.B., O'mara E., Wagner J.A., Butterton J.R., Dutko F.J., Moiseev V., Kobalava Z., Hüser A., Visan S., Schwabe C. ...Clinical Therapeutics. Vol. 40. 2018. P.. 704-718.e6
EFFECTS OF HEPATIC IMPAIRMENT ON THE PHARMACOKINETICS OF EVEROLIMUS: A SINGLE-DOSE, OPEN-LABEL, PARALLEL-GROUP STUDY ArticlePeveling-Oberhag J., Zeuzem S., Yong W.P., Kunz T., Paquet T., Bouillaud E., Urva S., Anak O., Sellami D., Kobalava Z.Clinical Therapeutics. Vol. 35. 2013. P.. 215-225
THE EFFECTS OF AMLODIPINE AND ENALAPRIL ON RENAL FUNCTION IN ADULTS WITH HYPERTENSION AND NONDIABETIC NEPHROPATHIES: A 3-YEAR, RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ArticleEsnault V.L.M., Brown E.A., Apetrei E., Bagon J., Calvo C., Dechatel R., Holdaas H., Krcmery S., Kobalava Z.Clinical Therapeutics. Vol. 30. 2008. P.. 482-498